Perspective Therapeutics (CATX) Liabilities and Shareholders Equity (2011 - 2026)

Perspective Therapeutics (CATX) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $410.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 24.72% year-over-year to $410.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 11.35% YoY), and the FY2025 full-year result was $267.0 million, down 21.73% from the prior year.
• Liabilities and Shareholders Equity improved to $410.8 million in Q1 2026, from $267.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $410.8 million in Q1 2026 to a low of $58.1 million in Q4 2022.
• A 5-year average of $218.6 million and a median of $267.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 253.93% in 2024 and decreased 24.63% in 2025, its largest moves.
• Tracing CATX's Liabilities and Shareholders Equity over 5 years: stood at $58.1 million in 2022, then surged by 68.51% to $97.9 million in 2023, then jumped by 248.45% to $341.1 million in 2024, then decreased by 21.73% to $267.0 million in 2025, then jumped by 53.86% to $410.8 million in 2026.
• Business Quant data shows CATX's Liabilities and Shareholders Equity at $410.8 million in Q1 2026, $267.0 million in Q4 2025, and $294.8 million in Q3 2025.